Urinary organs-at-risk for prostate cancer external beam radiotherapy: contouring guidelines on behalf of the Francophone Group of Urological Radiation Therapy (GFRU).

contouring external beam radiotherapy guidelines organs at risk prostate cancer stereotactic body radiation therapy

Journal

Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279

Informations de publication

Date de publication:
08 Jul 2024
Historique:
received: 23 04 2024
revised: 09 05 2024
accepted: 14 05 2024
medline: 11 7 2024
pubmed: 11 7 2024
entrez: 10 7 2024
Statut: aheadofprint

Résumé

Occurrence of genitourinary (GU) toxicity is a common adverse event observed after external beam radiotherapy (EBRT) for prostate cancer (PCa). Recent findings suggest that the dose delivered to specific urinary organs-at-risk (OARs) such as ureters, bladder trigone, and urethra is involved in the development of GU toxicity. A multidisciplinary task force including three radiation oncologists, a uroradiologist, and a urologist was created in 2022. First, OARs potentially involved in GU toxicity were identified and discussed. A literature review was performed, addressing several questions relative to urinary OARs: anatomical and radiological definition, radiation-induced injury, dose-volume parameters. Secondly, results were presented and discussed with a panel of radiation oncologists, members of the "Francophone Group of Urological Radiation Therapy" (GFRU). Thereafter, GFRU experts were asked to answer a dedicated questionnaire, including 35 questions on the controversial issues related to the delineation of urinary OARs. The following structures were identified as critical for PCa EBRT: ureters, bladder, bladder neck, bladder trigone, urethra (intraprostatic, membranous, spongious), striated sphincter, and post-enucleation or post-transurethral resection of the prostate (TURP) cavity. A consensus was obtained for 32 out of 35 items. This consensus highlights contemporary urinary structures in both upper and lower urinary tract to be considered for EBRT treatment planning of PCa. The current recommendations also propose a standardized definition of urinary OARs, for both daily practice and future clinical trials.

Identifiants

pubmed: 38986900
pii: S1879-8500(24)00145-0
doi: 10.1016/j.prro.2024.05.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest none

Auteurs

J Le Guévelou (J)

Department of radiation oncology, Centre Eugène Marquis, Rennes, France. Electronic address: Jennifer.leguevelou@gmail.com.

T Zilli (T)

Department of radiation oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.

L Ferretti (L)

Department of urology, MSP Bordeaux Bagatelle, Talence, France.

L Beuzit (L)

Department of radiology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.

O De Hertogh (O)

Department of radiation oncology, CHR Verviers East Belgium, Verviers, Belgium.

S Palumbo (S)

Department of radiation oncology, Hôpital de Jolimont, La Louvière, Belgium.

M Jolicoeur (M)

Department of radiation oncology, Charles LeMoyne Hospital, CISSS Montérégie-center, Montréal, Quebec, Canada.

G Crehange (G)

Department of radiation oncology, Institut Curie, Saint-Cloud, France.

T Derashodian (T)

Department of radiation oncology, Charles LeMoyne Hospital, CISSS Montérégie-center, Montréal, Quebec, Canada.

R De Crevoisier (R)

Department of radiation oncology, Centre Eugène Marquis, Rennes, France.

O Chapet (O)

Department of radiation oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France.

M Terlizzi (M)

Department of radiation oncology, Institut Gustave Roussy, Villejuif, France.

S Supiot (S)

Department of radiation oncology, Institut de Cancérologie de l'Ouest, Nantes Saint-Herblain, France; Unité en Sciences Biologiques et Biotechnologies, University of Nantes, Nantes, France.

C Salembier (C)

Department of radiation oncology, Europe Hospitals Brussels, Brussels, Belgium.

P Sargos (P)

Department of radiation oncology, Institut Bergonié, Bordeaux, France.

Classifications MeSH